Endothelial expression of endocan is strongly associated with tumor progression in pituitary adenoma

Brain Pathology

Volumn 22, Issue 6, 2012, Pages 757-764

  Cornelius, Aurélie ^a,b   Cortet Rudelli, Christine ^a,b   Assaker, Richard ^a,b   Kerdraon, Olivier ^a,b,c   Gevaert, Marie Hélène ^a   Prévot, Vincent ^c   Lassalle, Philippe ^d,e   Trouillas, Jacqueline ^f,g   Delehedde, Maryse ^d,e   Maurage, Claude Alain ^a,b,c  

^a UNIV LILLE   (France)

^b LILLE UNIVERSITY HOSPITAL   (France)

^c JEAN PIERRE AUBERT RESEARCH CENTER   (France)

^d INSERM U1019   (France)

^e Lunginnov   (France)

^f LYON NEUROSCIENCE RESEARCH CENTER   (France)

^g UNIVERSITÉ DE LYON   (France)

Author keywords

biomarker; endocan; ESM 1; pituitary adenoma

Indexed keywords

BIOLOGICAL MARKER; PROTEIN ENDOCAN; PROTEIN P53; PROTEOGLYCAN; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGED; ANGIOGENESIS; ANTIBODY LABELING; ARTICLE; AUTOPSY; CANCER PATIENT; CELL ISOLATION; CONTROLLED STUDY; ENDOCRINE CELL; ENDOTHELIUM; ENDOTHELIUM CELL; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPOPHYSIS ADENOMA; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MAJOR CLINICAL STUDY; MALE; MICROVASCULATURE; MITOSIS; MORPHOMETRICS; PROTEIN ANALYSIS; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR GROWTH; TUMOR VOLUME;

ADENOMA; ADOLESCENT; ADULT; AGED; DISEASE PROGRESSION; ENDOTHELIUM, VASCULAR; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; NEOPLASM PROTEINS; NEOVASCULARIZATION, PATHOLOGIC; PITUITARY NEOPLASMS; PROTEOGLYCANS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 84867573481     PISSN: 10156305     EISSN: 17503639     Source Type: Journal    
DOI: 10.1111/j.1750-3639.2012.00578.x     Document Type: Article

References (46)

1. Almog N, Ma L, Raychowdhury R, Schwager C, Erber R, Short S, et al, (2009) Transcriptional switch of dormant tumors to fast-growing angiogenic phenotype. Cancer Res 69: 836-844.
2. Bechard D, Gentina T, Delehedde M, Scherpereel A, Lyon M, Aumercier M, et al, (2001) Endocan is a novel chondroitin sulfate/dermatan sulfate proteoglycan that promotes hepatocyte growth factor/scatter factor mitogenic activity. J Biol Chem 276: 48341-48349.
3. Chen LY, Liu X, Wang SL, Qin CY, (2010) Over-expression of the Endocan gene in endothelial cells from hepatocellular carcinoma is associated with angiogenesis and tumour invasion. J Int Med Res 38: 498-510.
4. Cristina C, Perez-Millan MI, Luque G, Dulce RA, Sevlever G, Berner SI, Becu-Villalobos D, (2010) VEGF and CD31 association in pituitary adenomas. Endocr Pathol 21: 154-160.
5. Delehedde M, Sarrazin S, Adam E, Motte V, Vanpouille C, (2006) Proteoglycans and glycosaminoglycans: complex molecules with modulating activity. In: New Developments in Therapeutic Glycomics, M Delehedde, H Lortat-Jacob, (eds), pp. 1-13. Research Signpost: Kerala, India.
6. Del Toro R, Prahst C, Mathivet T, Siegfried G, Kaminker JS, Larrivee B, et al, (2010) Identification and functional analysis of endothelial tip cell-enriched genes. Blood 116: 4025-4033.
7. Ezzat S, Asa SL, Couldwell WT, Barr CE, Dodge WE, Vance ML, McCutcheon IE, (2004) The prevalence of pituitary adenomas: a systematic review. Cancer 101: 613-619.
8. Farnoud MR, Lissak B, Kujas M, Peillon F, Racadot J, Li JY, (1992) Specific alterations of the basement membrane and stroma antigens in human pituitary tumours in comparison with the normal anterior pituitary. An immunocytochemical study. Virchows Arch A Pathol Anat Histopathol 421: 449-455.
9. Fukui S, Otani N, Nawashiro H, Yano A, Miyazawa T, Ohnuki A, et al, (2002) Nuclear accumulation of basic fibroblast growth factor as a predictor for the recurrence of pituitary adenomas. J Neurooncol 57: 221-229.
10. Greenman Y, Ouaknine G, Veshchev I, Reider-Groswasser II, Segev Y, Stern N, (2003) Postoperative surveillance of clinically nonfunctioning pituitary macroadenomas: markers of tumour quiescence and regrowth. Clin Endocrinol (Oxf) 58: 763-769.
11. Grigoriu BD, Depontieu F, Scherpereel A, Gourcerol D, Devos P, Ouatas T, et al, (2006) Endocan expression and relationship with survival in human non-small cell lung cancer. Clin Cancer Res 12: 4575-4582.
12. Huang GW, Tao YM, Ding X, (2009) Endocan expression correlated with poor survival in human hepatocellular carcinoma. Dig Dis Sci 54: 389-394.
13. Janke J, Engeli S, Gorzelniak K, Feldpausch M, Heintze U, Böhnke J, et al, (2006) Adipose tissue and circulating endothelial cell specific molecule-1 in human obesity. Horm Metab Res 38: 28-33.
14. Lassalle P, Molet S, Janin A, Heyden JV, Tavernier J, Fiers W, et al, (1996) ESM-1 is a novel human endothelial cell-specific molecule expressed in lung and regulated by cytokines. J Biol Chem 271: 20458-20464.
15. Leroy X, Aubert S, Zini L, Franquet H, Kervoaze G, Villers A, et al, (2010) Vascular endocan (ESM-1) is markedly overexpressed in clear cell renal cell carcinoma. Histopathology 56: 180-187.
16. Liu N, Zhang LH, Du H, Hu Y, Zhang GG, Wang XH, et al, (2010) Overexpression of endothelial cell specific molecule-1 (ESM-1) in gastric cancer. Ann Surg Oncol 17: 2628-2639.
17. Lloyd RV, Scheithauer BW, Kuroki T, Vidal S, Kovacs K, Stefaneanu L, (1999) Vascular Endothelial Growth Factor (VEGF) expression in human pituitary adenomas and carcinomas. Endocr Pathol 10: 229-235.
18. Lloyd RV, Kovacs K, Young WF Jr, Farrell WE, Asa SL, Trouillas J, et al, (2004) Pituitary tumours: introduction. In: World Health Organization Classification of Tumors, Pathology and Genetics of Tumors of Endocrine Organs, A DeLellis, RV Lloyd, PU Heitz, C Eng, (eds), pp. 10-13. IARC Press: Lyon, France.
19. Losa M, Mortini P, Barzaghi R, Ribotto P, Terreni MR, Marzoli SB, et al, (2008) Early results of surgery in patients with nonfunctioning pituitary adenoma and analysis of the risk of tumor recurrence. J Neurosurg 108: 525-532.
20. Maurage CA, Adam E, Minéo JF, Sarrazin S, Debunne M, Siminski RM, et al, (2009) Endocan expression and localization in human glioblastomas. J Neuropathol Exp Neurol 68: 633-641.
21. Mukdsi JH, De Paul AL, Petiti JP, Gutiérrez S, Aoki A, Torres AI, (2006) Pattern of FGF-2 isoform expression correlated with its biological action in experimental prolactinomas. Acta Neuropathol 112: 491-501.
22. Niveiro M, Aranda FI, Peirõ G, Alenda C, Picõ A, (2005) Immunohistochemical analysis of tumor angiogenic factors in human pituitary adenomas. Hum Pathol 36: 1090-1095.
23. Nomura R, Yoshida D, Teramoto A, (2009) Stromal cell-derived factor-1 expression in pituitary adenoma tissues and upregulation in hypoxia. J Neurooncol 94: 173-181.
24. Onofri C, Theodoropoulou M, Losa M, Uhl E, Lange M, Arzt E, et al, (2006) Localization of vascular endothelial growth factor (VEGF) receptors in normal and adenomatous pituitaries: detection of a non-endothelial function of VEGF in pituitary tumours. J Endocrinol 191: 249-261.
25. Raverot G, Sturm N, de Fraipont F, Muller M, Salenave S, Caron P, et al, (2010) Temozolomide treatment in aggressive pituitary tumors and pituitary carcinomas: a French multicenter experience. J Clin Endocrinol Metab 95: 4592-4599.
26. Raverot G, Wierinckx A, Dantony E, Auger C, Chapas G, Villeneuve L, et al,; HYPOPRONOS (2010) Prognostic factors in prolactin pituitary tumors: clinical, histological, and molecular data from a series of 94 patients with a long postoperative follow-up. J Clin Endocrinol Metab 95: 1708-1716.
27. Recchia FM, Xu L, Penn JS, Boone B, Dexheimer PJ, (2010) Identification of genes and pathways involved in retinal neovascularization by microarray analysis of two animal models of retinal angiogenesis. Invest Ophthalmol Vis Sci 51: 1098-1105.
28. Rennel E, Mellberg S, Dimberg A, Petersson L, Botling J, Ameur A, et al, (2007) Endocan is a VEGF-A and PI3K regulated gene with increased expression in human renal cancer. Exp Cell Res 313: 1285-1294.
29. Sarrazin S, Adam E, Lyon M, Depontieu F, Motte V, Landolfi C, et al, (2006) Endocan or endothelial cell specific molecule-1 (ESM-1): a potential novel endothelial cell marker and a new target for cancer therapy. Biochim Biophys Acta 1765: 25-37.
30. Sarrazin S, Lyon M, Deakin JA, Guerrini M, Lassalle P, Delehedde M, Lortat-Jacob H, (2010) Characterization and binding activity of the chondroitin/dermatan sulphate chain from Endocan, a soluble endothelial proteoglycan. Glycobiology 20: 1380-1388.
31. Sarrazin S, Maurage CA, Delmas D, Lassalle P, Delehedde M, (2010) Endocan as a biomarker of endothelial dysfunction in cancer. J Cancer Sci Ther 2: 47-52.
32. Scherpereel A, Gentina T, Grigoriu B, Sénéchal S, Janin A, Tsicopoulos A, et al, (2003) Overexpression of endocan induces tumor formation. Cancer Res 63: 6084-6089.
33. Shin JW, Huggenberger R, Detmar M, (2008) Transcriptional profiling of VEGF-A and VEGF-C target genes in lymphatic endothelium reveals endothelial-specific molecule-1 as a novel mediator of lymphangiogenesis. Blood 112: 2318-2326.
34. Strasser GA, Kaminker JS, Tessier-Lavigne M, (2010) Microarray analysis of retinal endothelial tip cells identifies CXCR4 as a mediator of tip cell morphology and branching. Blood 115: 5102-5110.
35. Thapar K, Kovacs K, Scheithauer BW, Stefaneanu L, Horvath E, Pernicone PJ Jr, et al, (1996) Proliferative activity and invasiveness among pituitary adenomas and carcinomas: an analysis using the MIB-1 antibody. Neurosurgery 38: 99-106.
36. Thapar K, Scheithauer BW, Kovacs K, Pernicone PJ, Laws ER Jr, (1996) p53 expression in pituitary adenomas and carcinomas: correlation with invasiveness and tumor growth fractions. Neurosurgery 38: 765-770.
37. Thapar K, Yamada Y, Scheithauer B, Kovacs K, Yamada S, Stefaneanu L, (1996) Assessment of mitotic activity in pituitary adenomas and carcinomas. Endocr Pathol 7: 215-221.
38. Turner HE, Nagy Z, Gatter KC, Esiri MM, Wass JA, Harris AL, (2000) Proliferation, bcl-2 expression and angiogenesis in pituitary adenomas: relationship to tumour behaviour. Br J Cancer 82: 1441-1445.
39. Turner HE, Harris AL, Melmed S, Wass JA, (2003) Angiogenesis in endocrine tumors. Endocr Rev 24: 600-632.
40. Vidal S, Kovacs K, Horvath E, Scheithauer BW, Kuroki T, Lloyd RV, (2001) Microvessel density in pituitary adenomas and carcinomas. Virchows Arch 438: 595-602.
41. Vidal S, Horvath E, Kovacs K, Kuroki T, Lloyd RV, Scheithauer BW, (2003) Expression of hypoxia-inducible factor-1alpha (HIF-1alpha) in pituitary tumours. Histol Histopathol 18: 679-686.
42. Wellner M, Herse F, Janke J, Gorzelniak K, Engeli S, Bechart D, et al, (2003) Endothelial cell specific molecule-1-a newly identified protein in adipocytes. Horm Metab Res 35: 217-221.
43. Wierinckx A, Auger C, Devauchelle P, Reynaud A, Chevallier P, Jan M, et al, (2007) A diagnostic marker set for invasion, proliferation, and aggressiveness of prolactin pituitary tumors. Endocr Relat Cancer 14: 887-900.
44. Wierinckx A, Raverot G, Nazaret N, Jouanneau E, Auger C, Lachuer J, Trouillas J, (2010) Proliferation markers of human pituitary tumors: contribution of a genome-wide transcriptome approach. Mol Cell Endocrinol 326: 30-39.
45. Yoshida D, Kim K, Yamazaki M, Teramoto A, (2005) Expression of hypoxia-inducible factor 1alpha and cathepsin D in pituitary adenomas. Endocr Pathol 16: 123-131.
46. Zuo L, Zhang SM, Hu RL, Zhu HQ, Zhou Q, Gui SY, et al, (2008) Correlation between expression and differentiation of endocan in colorectal cancer. World J Gastroenterol 14: 4562-4568.